EMA’s human medicines committee qualifies first AI tool to diagnose inflammatory liver disease in biopsy samples: Amsterdam, The Netherlands Saturday, March 22, 2025, 16:00 Hrs ...

The European Medicines Agency (EMA) gave its approval to an artificial intelligence diagnostic tool for the first time on ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...

Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints ... and nonalcoholic steatohepatitis (NASH) to MASH. Additionally, an overarching term, ...

Otherwise, it would lead to diseases like acute (sudden) hepatitis (inflammation), chronic (long duration) hepatitis, fatty ...

The liver is essential for digestion, metabolism, detoxification, and fluid regulation. While alcohol abuse is a known cause ...

Four NASH datasets, GSE24807, GSE48452, GSE66676, and GSE63067 were retrieved from the GEO database, comprising a total of 119 human liver tissue samples, including 58 normal liver tissues and 61 NASH ...

An end-of-trial biopsy was assessed by 3 pathologists for histological endpoints using a consensus read approach. Liver biopsies were also analyzed using two independent AI-based digital pathology ...